Studies prognostic factors in advanced mycosis fungoides and Sézary syndrome
Collects patient data to predict survival in rare skin lymphomas called mycosis fungoides.
Plain-language title generated from the registry record
Registry title: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Key facts
- Where
- São Paulo, BrazilSee the site
Where in Brazil
- University of Sao Paulo Medical SchoolSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT02848274
- Record updated
- 22 October 2025
- Original description
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.Read full original descriptionShow less
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Inclusion: Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center; Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available.
Exclusion: Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center; Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage; Exclude one-time consultation type of new patients.